CCR1 and metastatic neoplasm: In these models, blockade of MAM accumulation via genetic deletion of CCR1, CCR2 or CCR5 significantly reduced metastatic tumor burden (43, 42, 86), suggesting that antagonists for these receptors can be novel therapeutic agents to prevent metastatic tumor development through inhibition of MAM accumulation.